Ketamine-Assisted Therapy vs. Medication Only: A Comparison

Ketamine-assisted therapy (KAT) pairs a ketamine dosing session with structured psychotherapy, typically preparation before the dose, a supported session during the drug's effects, and integration talk therapy afterward. Medication-only ketamine treatment delivers the same drug (as an intravenous infusion, intramuscular injection, or the FDA-approved nasal spray Spravato) without a built-in therapy component, though patients are usually still monitored by clinical staff during the session. Neither approach is FDA-approved for depression outside of esketamine (Spravato); generic ketamine for mental health conditions is prescribed off-label. Evidence for the medication effect itself is stronger and more consistent than evidence that adding formal talk therapy improves outcomes, though many clinicians and patients report the combination feels more meaningful and easier to sustain.

What Each Model Actually Involves

Medication-only ketamine treatment centers on the dosing session itself. A prescriber or clinic determines the route (IV, intramuscular, sublingual, or intranasal esketamine), monitors vital signs and psychological response during the session, and schedules follow-up dosing based on symptom tracking. Some clinics offer light conversation or a debrief afterward, but there is no formal therapeutic framework guiding what happens before or after the dose.

Ketamine-assisted therapy builds a psychotherapy structure around the same pharmacological treatment. A typical KAT program includes a preparation session with a therapist to set intentions and discuss what to expect, a dosing session where a trained clinician stays present and may offer light verbal support, and one or more integration sessions afterward to help the patient process the experience and connect it to therapeutic goals. Some KAT models use eye masks and music during dosing to encourage an inward-focused experience, an approach borrowed from psychedelic-assisted therapy research more broadly.

Where the Therapy Modality Varies

Not all ketamine-assisted therapy looks the same. Programs may draw on cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), or more experiential, insight-oriented approaches during integration. If you're comparing programs, ask what specific therapeutic framework they use and whether the same therapist stays with you across sessions, continuity matters for building trust and tracking progress, a point covered in more detail in this guide to questions about continuity of care.

What the Evidence Shows

The clearest, most replicated evidence in ketamine research is for the drug's rapid antidepressant effect, particularly in treatment-resistant depression. Randomized controlled trials and meta-analyses published in journals indexed on PubMed have repeatedly shown that ketamine infusions can reduce depressive symptoms within hours to days, an effect that traditional antidepressants typically take weeks to produce. This is the evidence base underlying esketamine's (Spravato) FDA approval, granted through the FDA's 2019 approval announcement for treatment-resistant depression in conjunction with an oral antidepressant.

Evidence specifically testing whether adding structured psychotherapy improves outcomes compared with medication alone is thinner. Smaller studies and clinical reports, often drawing on models developed for psychedelic-assisted therapy more broadly, suggest that pairing ketamine with therapy may extend symptom relief or help patients build coping skills, but sample sizes are generally small and study designs vary widely, making it hard to draw firm conclusions. The National Institute of Mental Health (NIMH) notes that ketamine's effects are typically time-limited, which is part of why maintenance dosing schedules and integration support are areas of active clinical interest rather than settled practice.

According to a widely cited 2000 study published in Biological Psychiatry, a single ketamine infusion produced rapid antidepressant effects in patients with treatment-resistant depression within 72 hours, a finding that helped launch decades of subsequent research into dosing protocols, but that study did not test a therapy-integration component. In short: the pharmacological effect is well-documented; the value of formal therapy layered on top is plausible and reported by many clinicians, but not yet proven with the same rigor.

Cost Differences Between the Two Models

Medication-only ketamine treatment is generally the less expensive option because you're paying for medical monitoring and the drug itself, not additional therapist hours. IV and intramuscular ketamine at a clinic commonly runs several hundred dollars per session, with a typical induction course of six sessions; sublingual or at-home telehealth options are often less expensive per dose. Esketamine (Spravato) is FDA-approved and may be covered by insurance for treatment-resistant depression, though patients typically still owe copays and must attend monitored in-office sessions, since the drug cannot be taken home.

Ketamine-assisted therapy adds the cost of therapist-led preparation and integration sessions on top of the medical fee, which can meaningfully raise the total price of a treatment course. Some clinics bundle these into a package rate; others bill therapy separately, sometimes through a therapist's own practice rather than the ketamine provider. Ask for a full breakdown of what's included before starting, and ask whether any component, the medical visit, the therapy, or both, might be covered by insurance. For a broader look at what drives cost up or down across ketamine treatment models generally, see the comparison of generic ketamine vs. Spravato.

Who Each Model Tends to Fit

Ketamine-assisted therapy may be a better fit if you're already engaged in psychotherapy and want to deepen that work, if you value having a consistent therapist relationship, or if you're processing trauma or grief alongside depression and want structured support for what can be an emotionally intense experience. It also suits patients who have the time and budget for a longer treatment course, since preparation and integration add real hours and cost.

Medication-only treatment may fit better if your priority is symptom relief on a tighter budget or timeline, if you already have an established therapist outside the ketamine clinic and don't want to duplicate that relationship, or if you're using esketamine through an insurance-covered pathway where the treatment protocol is standardized around FDA labeling rather than an add-on therapy model. Some patients also start with medication-only treatment and add therapy later if they want more support, the two approaches aren't mutually exclusive over time.

Whichever model you're considering, evidence quality and symptom fit still matter more than the therapy add-on itself. Review the condition-specific evidence in our guide to leading ketamine treatments for treatment-resistant depression before deciding between models.

Safety Screening Applies to Both Models

Neither model changes the underlying medical screening ketamine requires. Providers should review cardiovascular history, current medications, substance use history, and any history of psychosis before starting treatment, since ketamine can raise blood pressure and heart rate and carries dissociative effects that require monitoring. Our guide on who should not take ketamine covers these exclusion criteria in detail. If you're weighing at-home telehealth ketamine against a clinic-based program with or without therapy, the safety monitoring differences are covered in our comparison of IV ketamine vs. at-home ketamine and our broader look at telehealth ketamine vs. in-clinic treatment.

This article is educational and not medical advice. Talk with a licensed prescriber or therapist about your specific diagnosis, medical history, and treatment goals before starting any ketamine protocol.